Viatris 3Q 2026: Revenue $3.75B, EPS ($0.28) — 10-Q Summary
Viatris reported flat Q3 revenue of $3.75B and a net loss of $0.28 per share. Growth in Greater China and North America was offset by supply constraints and competition. Gross margin improved to 38% due to higher-margin product sales, while manufacturing disruptions cost $100M in revenue.
How this was made
The 30-second read
Why it matters
The earnings miss and operational issue are likely to weigh on the stock in the short term.
Market read
First‑report earnings data for a mid‑cap pharma firm, providing fresh material for traders.
What to watch
Potential upside from new estradiol transdermal products and growth in Greater China.
Background
Viatris released its Q3 2026 10‑Q, highlighting flat revenue, a widened net loss, and a $100 million negative impact from a plant suspension.
Ticker impact
Q3 2026 10-Q shows flat revenue and widened net loss, with a $100M hit from a plant suspension.
likely downside as investors price in the widened loss and $100M revenue hit
The report is the first disclosure of the quarter's results and includes a material negative impact from the Nashik facility.
Market effects
Generic drug manufacturers may see margin pressure from supply constraints.
Limited to US-listed pharma sector.
Modest, as Viatris is a mid-cap player.
Counterpoint
The revenue flatness could be a sign of stability in a volatile market, supporting a buy on dip.
Key entities
- companyViatris Inc.
US‑listed pharmaceutical company (ticker VTRS).
